RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 25 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 25

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Guizhou Medical University贵州医科大学附属医院GuiyangHospital page
  2. Study siteAffiliated Hospital of Hebei University河北大学附属医院ShijiazhuangHospital page
  3. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  4. Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
  5. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  6. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  7. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  8. Study siteFirst Hospital of Lanzhou University兰州大学第一医院LanzhouHospital page
  9. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  10. Study siteGeneral Hospital of Ningxia Medical University宁夏医科大学总医院YinchuanHospital page
  11. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  12. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  13. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  14. Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
  15. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  16. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  17. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  18. Study siteNanchang People's HospitalNanchangHospital page
  19. Study sitePeking University People's Hospital北京大学人民医院BeijingHospital page
  20. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  21. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  22. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  23. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  24. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  25. Study siteWeifang People's Hospital潍坊市人民医院WeifangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07876557, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);

    Inclusion criterion 3

  3. Previous treatment of any anti-VRGF drugs targeting VEGF (part 1) or ADC drugs targeting EGFR and/or HER3;

    Exclusion criterion 11

  4. ECOG performance status of 0 or 1;

    Inclusion criterion 6

  5. Measurable disease, as defined by RECIST v1.1;

    Inclusion criterion 8

  6. History of another malignancy within 5 years before the first dose of study drug;

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07876557, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Male or female age 18-70 years old;
  • Voluntary participation in clinical study;
  • Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);
  • No prior systemic antitumor therapy for locally advanced or Metastatic TNBC(cohort expansion period); only one line of prior systemetic treatment for locally advanced or metastatic TNBC;
  • Adequate organ function;
  • ECOG performance status of 0 or 1;
  • Life expectancy 12 weeks;
  • Measurable disease, as defined by RECIST v1.1;

Exclusion Criteria:

  • Untreated or active central nervous system (CNS) metastases;
  • Uncontrolled pleural effusion, pericardial effusion or ascites;
  • Tumor encasement of important vessels or significant necrosis and cavitation that may cause a risk of hemorrhage;
  • History of significant bleeding tendency or severe coagulation disorder;
  • Uncontrolled hypertension;
  • Active autoimmune diseases requiring systemic treatmen within 2 years prior to the first dose;
  • History of interstitial lung disease or previous Noninfectious pneumonitis treated with corticosteroids, or evidence of active Pneumonia in radiology on screening period;
  • History of immunodeficiency. Presence of active tuberculosis, hepatitis B, or hepatitis C;
  • Severe cardiovascular disease;
  • Serious infection (CTCAE 6.0 Grade>2) within 28 days prior to the first dose of study drug;
  • Previous treatment of any anti-VRGF drugs targeting VEGF (part 1) or ADC drugs targeting EGFR and/or HER3;
  • History of another malignancy within 5 years before the first dose of study drug;
  • Not suitable to receive study treatment for other conditions as per investigator;

Quoted from ClinicalTrials.gov, NCT07876557, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07876557, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07876557